Aimmune Therapeutics

General Information

We are a clinical-stage biopharmaceutical company advancing a new therapeutic approach, including the development of proprietary product candidates, for the treatment of peanut and other food allergies. It is estimated that over 30 million people in the United States and Europe have a food allergy, with peanut allergy being the most prevalent and most commonly associated with severe outcomes and life-threatening events. Our therapeutic approach, which we refer to as Characterized Oral Desensitization Immunotherapy, or CODIT, is a system designed to desensitize patients to food allergens using rigorously characterized biologic products, defined treatment protocols and tailored support services. In ARC001, our recently completed Phase 2 study of our lead CODIT product candidate, AR101, all of the 23 patients who completed the AR101 treatment regimen were desensitized to a clinically meaningful level of peanut protein of at least 443 mg, a level that substantially exceeds the amount of peanut protein typically encountered in an accidental exposure, which we believe to be approximately 100 mg or less. We intend to initiate a Phase 3 registration trial of AR101 in early 2016 and Phase 2 studies of other CODIT product candidates for two additional food allergies in 2016. AR101 has been granted Fast-Track designation and Breakthrough Therapy designation by the U.S. Food and Drug Administration, or FDA, and, if our planned Phase 3 program is successful, we intend to file a Biologics License Application, or BLA, with the FDA and a Marketing Authorization Application, or MAA, with the European Medicines Agency, or EMA. We have worldwide commercial rights to all of our product candidates and, if approved, we intend to commercialize in the United States and Europe with our own specialty sales force.

Employees: 21
Founded: 2011
Contact Information
Address 8000 Marina Blvd, Suite 300, Brisbane, CA 94005, US
Phone Number (650) 614-5220
Web Address
View Prospectus: Aimmune Therapeutics
Financial Information
Market Cap $650.9mil
Revenues $0.0 mil (last 12 months)
Net Income $-13.0 mil (last 12 months)
IPO Profile
Symbol AIMT
Exchange NASDAQ
Shares (millions): 10.0
Price range $16.00 - $16.00
Est. $ Volume $160.0 mil
Manager / Joint Managers BofA Merrill Lynch/ Credit Suisse/ Piper Jaffray
CO-Managers -
Expected To Trade: 8/6/2015
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change